M
Massimo Tommasino
Researcher at International Agency for Research on Cancer
Publications - 334
Citations - 14170
Massimo Tommasino is an academic researcher from International Agency for Research on Cancer. The author has contributed to research in topics: Cancer & HPV infection. The author has an hindex of 62, co-authored 312 publications receiving 12239 citations. Previous affiliations of Massimo Tommasino include German Cancer Research Center & World Health Organization.
Papers
More filters
Journal ArticleDOI
Risks for Persistence and Progression by Human Papillomavirus Type 16 variant lineages among a population-based sample of Danish Women
Tarik Gheit,Iris Cornet,Gary M. Clifford,Thomas Iftner,Christian Munk,Massimo Tommasino,Susanne K. Kjaer +6 more
TL;DR: Significant differences in risk for persistence exist between the HPV16 variants that predominate in Europe and are associated with a substantial absolute risk of progression to cervical intraepithelial neoplasia 3 or worse.
Journal ArticleDOI
Immunization of mice by oral colonization with live recombinant commensal streptococci.
TL;DR: To test the use of recombinant streptococci as live vaccine vectors, colonization/immunization experiments were performed with Streptococcus gordonii expressing heterologous cell-surface antigens, and it was found that this immune response depended upon the effective colonization by live bacteria.
Journal ArticleDOI
Case–Control Study of Cutaneous Human Papillomaviruses in Squamous Cell Carcinoma of the Skin
Michelle R. Iannacone,Tarik Gheit,Tim Waterboer,Anna R. Giuliano,Jane L. Messina,Neil A. Fenske,Basil S. Cherpelis,Vernon K. Sondak,Richard G. Roetzheim,Kristina M. Michael,Massimo Tommasino,Michael Pawlita,Dana E. Rollison +12 more
TL;DR: Genus-beta HPV infections were associated with SCC in the study population and identifying the role of cutaneous HPV infection in SCC may lead to improved characterization of high-risk individuals and the development of novel prevention strategies.
Journal ArticleDOI
HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6.
Hava Lichtig,Meirav Algrisi,Liat Edri Botzer,Tal Abadi,Yulia Verbitzky,Anna Jackman,Massimo Tommasino,Ingeborg Zehbe,Levana Sherman +8 more
TL;DR: Results of this study indicate that naturally occurring amino acid variations in HPV16 E6 can alter activities of the protein important for its carcinogenic potential.
Journal ArticleDOI
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Partha Basu,Sylla G. Malvi,Smita Joshi,Neerja Bhatla,Richard Muwonge,Eric Lucas,Yogesh Verma,Pulikkottil Okkuru Esmy,Usha Rani Reddy Poli,Anand Shah,Eric Zomawia,Sharmila Pimple,Kasturi Jayant,Sanjay Hingmire,Aruna Chiwate,Uma Divate,Shachi Vashist,Gauravi A Mishra,Radhika Jadhav,Maqsood Siddiqi,Subha Sankaran,Priya R. Prabhu,Thiraviam Pillai Rameshwari Ammal Kannan,Rintu Varghese,Surendra S Shastri,Devasena Anantharaman,Tarik Gheit,Massimo Tommasino,Catherine Sauvaget,M. Radhakrishna Pillai,Rengaswamy Sankaranarayanan +30 more
TL;DR: In this article, the authors compared the vaccine efficacy of single dose to that of three and two doses in protecting against persistent HPV 16 and 18 infection at 10 years post vaccination, and concluded that a single dose of vaccine provides similar protection against persistent infection from HPV 16, the genotypes responsible for nearly 70% of cervical cancers, to that provided by two or three doses.